NSE · ACCENTMIC
Accent Microcell Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹356 Cr with net profit ₹44 Cr — a 12.33% net margin, versus 12.2% the period before.
Shareholding
As of 2026-09-30
- Promoter51.4%
- Public45.46%
- FII0.72%
- DII2.43%
3,371 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.89× from low to high.
Risk flags
Derived from disclosed data
- Promoter holding fell 1.63 percentage points to 51.4% in the latest disclosure.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #51 of 102 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,20,771 Cr | 33.3 | 5.03 | 13.74% | 20.29% |
| Zydus Lifesciences Ltd. | ₹1,14,154 Cr | 23.38 | 4.21 | 18.59% | 16.09% |
| Laurus Labs Limited | ₹1,09,370 Cr | 100.01 | 20.64 | 16.77% | 15.04% |
| Cipla Ltd. | ₹1,08,513 Cr | 30.32 | 3.15 | 11.27% | 12.06% |
| Dr Reddys Laboratories Ltd. | ₹1,08,266 Cr | 33.6 | 2.84 | 7.21% | 8.49% |
| Mankind Pharma Limited | ₹93,071 Cr | 43.63 | 5.71 | 11.74% | 13.86% |
| Aurobindo Pharma Ltd. | ₹90,340 Cr | 23.89 | 2.38 | 9.25% | 10.7% |
| Lupin Limited | ₹88,444 Cr | 14.85 | 3.94 | 23.76% | 18.72% |
| Glenmark Pharmaceuticals Ltd. | ₹62,346 Cr | 19.98 | 5.93 | 28.08% | 10.22% |
| Alkem Laboratories Ltd. | ₹59,442 Cr | 26.09 | 4.3 | 16.66% | 14.31% |
| Accent Microcell Limited(this company) | ₹1,492 Cr | 34.03 | 5.42 | 18.71% | 12% |
AI analysis
AI-generated · google/gemini-2.5-flashAccent Microcell Limited is listed with a market capitalization of Rs 1266 Cr. The company reported a revenue of Rs 355.8 Cr and an EPS of Rs 18.28. The book value per share stands at Rs 114.84.
Positives
- +Revenue grew from Rs 167.5397 Cr in March 2022 to Rs 355.7995 Cr in March 2026.
- +Net profit increased from Rs 5.8931 Cr in March 2022 to Rs 43.8586 Cr in March 2026.
- +The debt-to-equity ratio is low at 0.04.
- +Return on Capital Employed (ROCE) is 21.277%.
Negatives
- −The profit margin is reported as 0%, which may indicate missing or undefined data.
- −Quarterly results are not available after March 2023, making recent performance analysis difficult.
- −Promoter holding decreased from 73.1302% in October 2023 to 55.4664% in March 2026.
- −The dividend yield is high at 19%, which may warrant further investigation into its sustainability.
Financial performance
Accent Microcell Limited's annual revenue has shown growth, increasing from Rs 167.5397 Cr in March 2022 to Rs 355.7995 Cr in March 2026. Net profit also rose from Rs 5.8931 Cr in March 2022 to Rs 43.8586 Cr in March 2026. The EPS increased from Rs 4.57 in March 2022 to Rs 18.65 in March 2026.
Profitability & returns
The company recorded a Return on Equity (ROE) of 15.92% and a Return on Capital Employed (ROCE) of 21.277%. The latest reported profit margin is 0%. The EPS for the latest period was Rs 18.28.
Balance sheet
Accent Microcell Limited maintains a debt-to-equity ratio of 0.04, indicating a low reliance on debt financing. The book value per share is Rs 114.84. No information is available for quarterly results after March 2023.
Ownership & pledges
As of March 31, 2026, promoters held 55.4664% of the company's shares. Public shareholding was 40.3602%, while FIIs held 0.5815% and DIIs held 3.5919%. There were no promoter share pledges reported.
Data as of — price: 2026-10-26 · financials: Mar 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.